Neurological research · 2025
Comparison of levodopa response rate in association with clinical features in Parkinson's disease subjects with and without STN-DBS.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Onder Halil, Comoglu Selcuk
Аннотация
BACKGROUND: The levodopa response (LR) in patients with deep brain stimulation of the subthalamic nucleus (STN-DBS) has rarely been investigated. We sought to investigate the LR, and clinical features associated with STN-DBS therapy.
METHODS: PD subjects with and without STN-DBS who applied to our movement disorders outpatient clinics between January 2023 and July 2023 were evaluated. The clinical features and detailed clinical scales, including MDS-UPDRS, FOGQ, FES, VHI, and PDQ-39 were administered. LR was measured by calculating the percent medication-'off' to 'on' change in the MDS-UPDRS-3 scores.
RESULTS: Overall, 169 patients with PD participated in this study (35 patients with STN-DBS, and 134 patients without STN-DBS). The mean age of the patients was 60.9 ± 8.8 y (F/M = 66/103), and the disease duration was 7y. The comparative analyses revealed that the disease duration, the MDS-UPDRS-2 and MDS-UPDRS-3 'off' scores were higher in the DBS group. In addition, the scores for axial features such as VHI, FOGQ, and FES-I were higher in the DBS group. However, the LR percentage did not differ between groups (0.47 versus 0.44, p = 0.095). The regression analyses revealed LR rate (B = 5.547, p < 0.01), disease duration (B = 0.349, p < 0.001), and FOGQ (B = 0.175, p < 0.01) as predictors of STN-DBS group.
CONCLUSIONS: LR was similar between patients with and without STN-DBS, suggesting that non-dopaminergic mechanisms contribute to the efficacy of STN-DBS while underscoring the continued importance of dopaminergic therapy in these patients.
METHODS: PD subjects with and without STN-DBS who applied to our movement disorders outpatient clinics between January 2023 and July 2023 were evaluated. The clinical features and detailed clinical scales, including MDS-UPDRS, FOGQ, FES, VHI, and PDQ-39 were administered. LR was measured by calculating the percent medication-'off' to 'on' change in the MDS-UPDRS-3 scores.
RESULTS: Overall, 169 patients with PD participated in this study (35 patients with STN-DBS, and 134 patients without STN-DBS). The mean age of the patients was 60.9 ± 8.8 y (F/M = 66/103), and the disease duration was 7y. The comparative analyses revealed that the disease duration, the MDS-UPDRS-2 and MDS-UPDRS-3 'off' scores were higher in the DBS group. In addition, the scores for axial features such as VHI, FOGQ, and FES-I were higher in the DBS group. However, the LR percentage did not differ between groups (0.47 versus 0.44, p = 0.095). The regression analyses revealed LR rate (B = 5.547, p < 0.01), disease duration (B = 0.349, p < 0.001), and FOGQ (B = 0.175, p < 0.01) as predictors of STN-DBS group.
CONCLUSIONS: LR was similar between patients with and without STN-DBS, suggesting that non-dopaminergic mechanisms contribute to the efficacy of STN-DBS while underscoring the continued importance of dopaminergic therapy in these patients.